Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$420K Hold
1,160
0.44% 23
2026
Q1
$380K Hold
1,160
0.45% 22
2025
Q4
$380K Hold
1,160
0.45% 22
2025
Q3
$327K Hold
1,160
0.4% 24
2025
Q2
$324K Hold
1,160
0.42% 23
2025
Q1
$361K Hold
1,160
0.51% 20
2024
Q4
$302K Hold
1,160
0.4% 16
2024
Q3
$374K Hold
1,160
0.46% 14
2024
Q2
$362K Hold
1,160
0.48% 13
2024
Q1
$330K Hold
1,160
0.43% 13
2023
Q4
$334K Hold
1,160
0.56% 15
2023
Q3
$312K Hold
1,160
0.59% 15
2023
Q2
$258K Hold
1,160
0.59% 13
2023
Q1
$280K Hold
1,160
0.55% 15
2022
Q4
$305K Hold
1,160
0.62% 13
2022
Q3
$261K Hold
1,160
0.39% 15
2022
Q2
$282K Hold
1,160
0.29% 19
2022
Q1
$281K Hold
1,160
0.23% 20
2021
Q4
$261K Buy
+1,160
New +$245K 0.18% 23

Other funds holding AMGN

Capitol Family Office's AMGN Position: Q2 2026 in Review

Capitol Family Office held its Amgen (AMGN) position steady in Q2 2026 at 1,160 shares worth $420K. The position accounts for 0.44% of the portfolio, ranked #23.

Capitol Family Office first reported a position in AMGN in Q4 2021 and has held it in 19 quarters since. 1,848 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Capitol Family Office held 1,160 shares of Amgen worth $420K as of Q2 2026.
  • Capitol Family Office left its Amgen share count unchanged in Q2 2026.
  • Amgen made up 0.44% of Capitol Family Office's portfolio in Q2 2026, its #23 holding.
  • Capitol Family Office first reported a position in Amgen in Q4 2021 and has held it in 19 quarters since.
  • 1,848 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Capitol Family Office's 13F filing for Q2 2026, filed 31 Jul 2026.